Lakewood-Amedex Biotherapeutics (LABT) surged over 70% premarket, a day after listing on Nasdaq. The biotech closed Thursday up 8% with a $122M cap. Chairman Doug Manion said the listing accelerates the development of its bisphosphocin compounds. The firm plans a Phase 2a clinical trial for Nu-3 to treat infected diabetic foot ulcers.